GPR107-EGFR crosstalk promotes ovarian cancer metastasis by regulating IL-6 release via PI3K/AKT/NF-κB signaling pathway
Open Access
- 18 June 2026
- journal article
- Published by Elsevier in Translational Oncology
- Vol. 71, 102867
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Shanghai Municipality
This publication has 49 references indexed in Scilit:
- The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patientsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Neuronostatin Promotion Soluble Aβ1-42 Oligomers: Induced Dysfunctional Brain Glucose Metabolism in MiceNeurochemical Research, 2020
- Neuronostatin promotes soluble Aβ1-42 oligomers –induced spatial learning and memory impairments in miceBehavioural Brain Research, 2019
- The positive predictive value of low‐density lipoprotein for recurrence‐free survival in ovarian cancerInternational Journal of Gynecology & Obstetrics, 2018
- GPCRs and EGFR – Cross-talk of membrane receptors in cancerBioorganic & Medicinal Chemistry Letters, 2017
- Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based ChemotherapyTargeted Oncology, 2015
- CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer CellsJournal of Molecular Neuroscience, 2015
- Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancerCancer Chemotherapy and Pharmacology, 2014
- The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancerCancer Epidemiology, 2012
- Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathwayThe Prostate, 2000